

## **Global Endometriosis Treatment Market Report and Forecast 2024-2032**

Market Report | 2024-07-19 | 200 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

### **Report description:**

Global Endometriosis Market Report and Forecast 2024-2032

The global endometriosis market size was valued at USD 1.5 billion in 2023. It is expected to grow at a CAGR of 13.10% during the forecast period of 2024-2032, driven by the increased advocacy and awareness efforts by organisations. The market is experiencing robust growth and is expected to reach USD 4.5 billion by 2032.

Global Endometriosis Market Analysis

Endometriosis is a chronic and often painful condition where tissue similar to the lining of the uterus starts to grow outside the uterine cavity, primarily on the ovaries, bowel, and tissues lining the pelvis. The global market for endometriosis is evolving due to the increasing prevalence of the disease, rising awareness, and ongoing research into new treatments. Here's an analysis of the current market, including drivers, challenges, and future opportunities:

#### **Market Drivers**

- ☐ **Increasing Prevalence:** The number of women diagnosed with endometriosis is rising, driven by better awareness and improved diagnostic techniques. This increase in diagnosed cases directly expands the target market for endometriosis treatments.
- ☐ **Advancements in Diagnostic Technologies:** New imaging technologies and diagnostic criteria make it easier to diagnose endometriosis earlier and more accurately, increasing the demand for targeted treatment solutions.
- ☐ **Growing Awareness and Advocacy:** Increased advocacy and awareness efforts by organisations and influencers have led to greater recognition of the condition and a higher demand for medical services related to endometriosis.
- ☐ **Research and Development:** There is significant investment in researching and developing new treatments for endometriosis, including hormone therapy and novel non-hormonal drugs, which can drive market growth.

#### **Market Challenges**

- ☐ **High Cost of Treatment:** The cost of treating endometriosis, especially surgical interventions, remains high, which can be a barrier for many patients, affecting market growth in lower-income regions.
- ☐ **Diagnostic Delays:** Endometriosis often requires a long time to diagnose correctly, sometimes several years, due to its symptoms resembling other conditions. This delay can restrict the timely treatment of patients and affect their quality of life.
- ☐ **Lack of Curative Therapy:** Currently, there is no definitive cure for endometriosis. Most treatments focus on managing symptoms rather than curing the disease, which can lead to dissatisfaction among patients and a continued search for effective solutions.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

-□Side Effects of Current Treatments: Many treatments, particularly hormonal therapies, have significant side effects that can deter patients from continuing with them.

#### Future Opportunities

-□Innovative Therapeutic Developments: There is substantial opportunity for the development of new drugs that offer better efficacy with fewer side effects, including non-hormonal therapies that can address patients' needs without the hormonal side effects.

-□Personalised Medicine: Advances in genomics and biotechnology could lead to personalised treatment plans tailored to the genetic profiles of individuals, improving treatment outcomes.

-□Global Health Initiatives: Increasing involvement of global health organisations in promoting women's health can help increase funding and support for endometriosis research and treatment accessibility.

-□Alternative and Complementary Therapies: There is a growing interest in alternative treatments, which could open new avenues for companies to explore products outside traditional pharmaceuticals, such as dietary supplements and holistic therapies.

-□Partnerships and Collaborations: Partnerships between pharmaceutical companies and biotech firms can accelerate the development of new treatments and expand market reach through combined expertise and resources.

#### Global Endometriosis Market Trends

The global endometriosis market is shaped by several emerging trends that influence both the development of new treatments and the overall market dynamics. Here are some key trends currently impacting this market:

##### -□Increasing Investment in R&D

Research and development activities in the field of endometriosis are gaining momentum as pharmaceutical companies and biotech firms strive to find more effective and safer treatments. This includes exploring novel non-hormonal therapies, which are highly anticipated due to the potential for fewer side effects compared to traditional hormone-based treatments.

##### -□Shift Towards Non-Invasive Treatments

There is a growing trend towards non-invasive or minimally invasive treatments for endometriosis. Medical device companies are developing innovative products like advanced imaging systems and surgical instruments that enhance the precision of laparoscopic procedures, reducing recovery time and improving outcomes.

##### -□Focus on Early Diagnosis

Early diagnosis of endometriosis is becoming a priority, as it can significantly improve the quality of life for patients by enabling earlier intervention. Advances in diagnostic technologies, such as improved ultrasound techniques and potential biomarkers in blood or other body fluids, are crucial trends in this area.

##### -□Personalised and Precision Medicine

The trend towards personalised medicine is becoming more pronounced in the treatment of endometriosis. Understanding individual genetic, molecular, and clinical profiles helps in tailoring specific treatment regimens that are more effective and have fewer side effects for individual patients.

##### -□Increased Awareness and Advocacy

Global awareness campaigns and advocacy by various health organisations and celebrities have helped increase the visibility of endometriosis. These efforts are not only educating the public and healthcare providers but also encouraging more women to seek medical advice early. Increased awareness can lead to higher diagnostic rates and a greater demand for treatment solutions.

##### -□Regulatory Support for Faster Approval

Regulatory agencies are offering faster pathways for the approval of drugs that treat conditions like endometriosis, which have historically been underserved. This support can help reduce the time it takes for new therapies to reach the market, benefiting both patients and pharmaceutical companies.

##### -□Expansion into Emerging Markets

As healthcare access improves in emerging markets, there is increasing potential for growth in these regions. Pharmaceutical companies are looking to expand their reach by distributing existing and new treatments to countries with developing healthcare systems, where awareness of endometriosis is also rising.

##### -□Integration of Digital Health Solutions

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

The integration of digital health technologies, including telehealth and mobile health apps, into patient management for endometriosis is a growing trend. These technologies can help in managing symptoms, tracking disease progression, and improving patient engagement and compliance with treatment protocols.

These trends indicate a dynamic and evolving endometriosis market, with ongoing innovations and improvements in treatment approaches and patient care. As these trends continue to develop, they are expected to drive significant changes in how endometriosis is diagnosed, treated, and managed globally.

#### Global Endometriosis Market Segmentation

##### Market Breakup by Type

- Superficial Peritoneal Endometriosis
- Endometriomas
- Deeply Infiltrating Endometriosis
- Others

The global endometriosis market is segmented by type into superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and others. Each segment is poised to drive market growth during the forecast period due to unique factors. Superficial peritoneal endometriosis, being the most common form, has a high demand for diagnostic and therapeutic solutions, driving innovation and treatment approaches. Endometriomas, often requiring surgical intervention, push advancements in minimally invasive surgeries. Deeply infiltrating endometriosis, known for its severity, drives the demand for highly effective pain management and innovative drug therapies. Other less common types also contribute to diversifying treatment options and expanding research opportunities. Collectively, these segments, fueled by rising disease awareness and technological advancements, are set to significantly influence the overall market growth.

##### Market Breakup by Treatment Type

- Hormonal Therapy
- Pain Management
- Others

The global endometriosis market, segmented by treatment type, includes hormonal therapy, pain management, and others. Hormonal therapy, the cornerstone treatment, dominates due to its efficacy in managing the disease's progression and symptoms, promising continued growth with innovations in drug formulations. Pain management, critical for improving patient quality of life, is expanding with advancements in non-opioid medications and integrative approaches, indicating robust market potential. The 'others' segment, encompassing emerging treatments like immunotherapies and cell-based therapies, is poised to revolutionise treatment paradigms. Together, these segments, driven by increasing prevalence, improved diagnostic methods, and patient-centric approaches, are set to propel market growth significantly during the forecast period.

##### Market Breakup by Drug Class

- Oral Contraceptives
- Progestins
- NSAIDs
- GnRH Analogues
- LNR-IUDs
- Others

In the global endometriosis market, segmentation by drug class includes oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDs, and others. Oral contraceptives are widely used due to their dual benefits of menstrual regulation and pain relief, ensuring steady market growth. Progestins are favored for their effectiveness in reducing endometrial growth with fewer side effects, supporting strong market traction. NSAIDs, commonly used for immediate pain relief, remain essential despite the rise of specific treatments. GnRH analogues and LNR-IUDs are growing due to their targeted action and long-term benefits, respectively. The 'others' category, which includes new drug developments and combination therapies, is also expanding as research progresses. This diverse range of drug classes, driven by ongoing advancements and increasing demand for effective management options, is crucial for driving the market's growth in the forecast period.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

#### Market Breakup by End User

- Hospitals
- Specialty Clinics
- Others

The global endometriosis market is segmented by end users into hospitals, specialty clinics, and others. Hospitals, as primary treatment centers offering comprehensive care, are anticipated to lead the market due to their capability to provide advanced surgical and diagnostic facilities. Specialty clinics are also significant contributors, particularly appealing for their specialised focus on gynecological disorders like endometriosis, which facilitates targeted treatments and expert care. The 'others' segment, including home care settings and research institutions, is expanding with the adoption of telehealth services and patient-centric home therapies. These segments, supported by technological advancements and an increasing emphasis on specialised healthcare, are poised to drive substantial growth in the endometriosis market during the forecast period.

#### Market Breakup by Distribution Channel

- Hospital Pharmacies
- Retail Pharmacies
- Drugstores
- E-Commerce
- Others

The global endometriosis market, segmented by distribution channel, includes hospital pharmacies, retail pharmacies, drugstores, e-commerce, and others. Hospital pharmacies hold a significant share due to their direct link with healthcare facilities, ensuring immediate access to prescribed treatments. Retail pharmacies are also crucial, providing widespread availability and convenience for patients. Drugstores complement this landscape by offering over-the-counter pain management solutions. E-commerce is rapidly growing, driven by the convenience of home delivery and increasing consumer preference for online shopping, which is expanding access to medications and health products. The 'others' segment, which might include specialty stores or direct distribution from manufacturers, is benefiting from personalised service and patient support programs. Together, these channels facilitate extensive drug availability and are essential for meeting the diverse needs of endometriosis patients, significantly impacting market dynamics during the forecast period.

#### Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

The global endometriosis market is segmented regionally into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads the market due to advanced healthcare infrastructure, high awareness levels, and substantial investment in research and development. Europe follows closely, with strong government support for healthcare and numerous initiatives to improve disease recognition and management. The Asia Pacific region is the fastest-growing, driven by increasing healthcare spending, improving diagnostic facilities, and rising awareness. Latin America and the Middle East and Africa are emerging markets, where growth is fueled by gradual improvements in healthcare systems and growing access to treatment. Collectively, these regional markets, each with unique growth drivers and challenges, contribute significantly to the global expansion and dynamics of the endometriosis market.

#### Global Endometriosis Market Competitive Landscape

The competitive landscape of the global endometriosis market is vibrant and features key players such as Bayer AG, Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca, Myovant Sciences, Ipsen Pharma, Sun Pharmaceutical Industries Limited, Cipla Limited, Zydus Healthcare Limited, Lannett, Sandoz AG, TerSera Therapeutics USA, Tolmar Pharmaceuticals, and Endoceutics, Inc. These companies are actively engaged in various market activities to strengthen their positions, including

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

mergers and acquisitions, forming strategic partnerships, launching new products, and investing in research and development initiatives. For instance, mergers and acquisitions are common as larger companies aim to enhance their product portfolios and expand their global reach. Research and development are particularly focused on innovating drug formulations and discovering new therapeutic targets, while product introductions often involve improved treatment options with fewer side effects. Partnerships, often seen between industry giants and biotech firms, facilitate the sharing of expertise and accelerate drug development and market entry.

#### Key Questions Answered in the Report

- ?□What is the current and future performance of the global endometriosis market?
- ?□What are the main challenges facing the global endometriosis market?
- ?□What are the key drivers of the endometriosis market?
- ?□What emerging trends are shaping the future of the global endometriosis market?
- ?□What are the benefits of non-invasive treatments for endometriosis?
- ?□How do global awareness campaigns improve early diagnosis rates for endometriosis?
- ?□How do specialty clinics enhance treatment outcomes for endometriosis patients?
- ?□How does government support in Europe improve endometriosis disease recognition and management?
- ?□What are the common strategies used by key players in the global endometriosis market?

#### Key Benefits for Stakeholders

- ?□The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global endometriosis market from 2017-2032.
- ?□The research report provides the latest information on the market drivers, challenges, and opportunities in the global endometriosis market.
- ?□The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- ?□Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyse the level of competition within the global endometriosis industry and its attractiveness.
- ?□The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

#### Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
- 2 Research Methodology
- 3 Executive Summary
- 4 Endometriosis Overview
  - 4.1 Guidelines and Stages
  - 4.2 Pathophysiology
  - 4.3 Screening and Diagnosis
  - 4.4 Treatment Pathway
- 5 Patient Profile
  - 5.1 Patient Profile Overview
  - 5.2 Patient Psychology and Emotional Impact Factors
  - 5.3 Risk Assessment and Treatment Success Rate
- 6 Current Scenario Evaluation and Regulatory Framework

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 6.1 Emerging Therapies and Clinical Trials
- 6.2 Patent Landscape
  - 6.2.1 Patent Overview
    - 6.2.1.1 Patent Status and Expiry
    - 6.2.1.2 Timelines from Drug Development to Commercial Launch
    - 6.2.1.3 New Drug Application
      - 6.2.1.3.1 Documentation and Approval Process
- 6.3 Cost of Treatment
- 6.4 Regulatory Framework
  - 6.4.1 Regulatory Overview
    - 6.4.1.1 US FDA
    - 6.4.1.2 EU EMA
    - 6.4.1.3 INDIA CDSCO
    - 6.4.1.4 JAPAN PMDA
    - 6.4.1.5 Others
- 7 Challenges and Unmet Needs
  - 7.1 Treatment Pathway Challenges
  - 7.2 Compliance and Drop-Out Analysis
  - 7.3 Awareness and Prevention Gaps
- 8 Global Endometriosis Treatment Market
  - 8.1 Global Endometriosis Treatment Market Overview
  - 8.2 Global Endometriosis Treatment Market Analysis
    - 8.2.1 Market Overview
      - 8.2.1.1 Global Endometriosis Treatment Market Historical Value (2017-2023)
      - 8.2.1.2 Global Endometriosis Treatment Market Forecast Value (2024-2032)
    - 8.2.2 Global Endometriosis Treatment Market by Indication Type
      - 8.2.2.1 Market Overview
        - 8.2.2.1.1 Superficial Peritoneal Lesion
        - 8.2.2.1.2 Endometrioma
        - 8.2.2.1.3 Deeply Infiltrating Endometriosis
        - 8.2.2.1.4 Others
    - 8.2.3 Global Endometriosis Treatment Market by Diagnostic Method
      - 8.2.3.1 Market Overview
        - 8.2.3.1.1 Ultrasound
        - 8.2.3.1.2 Pelvic Examination
        - 8.2.3.1.3 Laparoscopy
        - 8.2.3.1.4 Magnetic Resonance Imaging
        - 8.2.3.1.5 Others
    - 8.2.4 Global Endometriosis Treatment Market by Treatment Method
      - 8.2.4.1 Market Overview
        - 8.2.4.1.1 Hormonal Therapy
        - 8.2.4.1.2 Pain Management
        - 8.2.4.1.3 Others
    - 8.2.5 Global Endometriosis Treatment Market by Drug Class
      - 8.2.5.1.1 Oral Contraceptives
      - 8.2.5.1.2 Progestins
      - 8.2.5.1.3 NSAIDs

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.2.5.1.4 GnRH Analogues
- 8.2.5.1.5 Others
- 8.2.6 Global Endometriosis Treatment Market by Distribution Channel
  - 8.2.6.1 Market Overview
    - 8.2.6.1.1 Hospital Pharmacies
    - 8.2.6.1.2 Retail Pharmacies
    - 8.2.6.1.3 Online Pharmacies
- 8.2.7 Global Endometriosis Treatment Market by Region
  - 8.2.7.1 Market Overview
    - 8.2.7.1.1 North America
    - 8.2.7.1.2 Europe
    - 8.2.7.1.3 Asia Pacific
    - 8.2.7.1.4 Latin America
    - 8.2.7.1.5 Middle East and Africa
- 9 North America Endometriosis Treatment Market
  - 9.1 Market Share by Country
  - 9.2 United States of America
    - 9.2.1 Historical Trend (2017-2023)
    - 9.2.2 Forecast Trend (2024-2032)
  - 9.3 Canada
    - 9.3.1 Historical Trend (2017-2023)
    - 9.3.2 Forecast Trend (2024-2032)
- 10 Europe Endometriosis Treatment Market
  - 10.1 Market Share by Country
  - 10.2 United Kingdom
    - 10.2.1 Historical Trend (2017-2023)
    - 10.2.2 Forecast Trend (2024-2032)
  - 10.3 Germany
    - 10.3.1 Historical Trend (2017-2023)
    - 10.3.2 Forecast Trend (2024-2032)
  - 10.4 France
    - 10.4.1 Historical Trend (2017-2023)
    - 10.4.2 Forecast Trend (2024-2032)
  - 10.5 Italy
    - 10.5.1 Historical Trend (2017-2023)
    - 10.5.2 Forecast Trend (2024-2032)
  - 10.6 Others
- 11 Asia Pacific Endometriosis Treatment Market
  - 11.1 Market Share by Country
  - 11.2 China
    - 11.2.1 Historical Trend (2017-2023)
    - 11.2.2 Forecast Trend (2024-2032)
  - 11.3 Japan
    - 11.3.1 Historical Trend (2017-2023)
    - 11.3.2 Forecast Trend (2024-2032)
  - 11.4 India
    - 11.4.1 Historical Trend (2017-2023)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.4.2 Forecast Trend (2024-2032)
- 11.5 ASEAN
  - 11.5.1 Historical Trend (2017-2023)
  - 11.5.2 Forecast Trend (2024-2032)
- 11.6 Australia
  - 11.6.1 Historical Trend (2017-2023)
  - 11.6.2 Forecast Trend (2024-2032)
- 11.7 Others
- 12 Latin America Endometriosis Treatment Market
  - 12.1 Market Share by Country
  - 12.2 Brazil
    - 12.2.1 Historical Trend (2017-2023)
    - 12.2.2 Forecast Trend (2024-2032)
  - 12.3 Argentina
    - 12.3.1 Historical Trend (2017-2023)
    - 12.3.2 Forecast Trend (2024-2032)
  - 12.4 Mexico
    - 12.4.1 Historical Trend (2017-2023)
    - 12.4.2 Forecast Trend (2024-2032)
  - 12.5 Others
- 13 Middle East and Africa Endometriosis Treatment Market
  - 13.1 Market Share by Country
  - 13.2 Saudi Arabia
    - 13.2.1 Historical Trend (2017-2023)
    - 13.2.2 Forecast Trend (2024-2032)
  - 13.3 United Arab Emirates
    - 13.3.1 Historical Trend (2017-2023)
    - 13.3.2 Forecast Trend (2024-2032)
  - 13.4 Nigeria
    - 13.4.1 Historical Trend (2017-2023)
    - 13.4.2 Forecast Trend (2024-2032)
  - 13.5 South Africa
    - 13.5.1 Historical Trend (2017-2023)
    - 13.5.2 Forecast Trend (2024-2032)
  - 13.6 Others
- 14 Global Endometriosis Treatment Market Dynamics
  - 14.1 Market Drivers and Constraints
  - 14.2 SWOT Analysis
  - 14.3 Porter's Five Forces Model
  - 14.4 Key Demand Indicators
  - 14.5 Key Price Indicators
  - 14.6 Industry Events, Initiatives, and Trends
  - 14.7 Value Chain Analysis
- 15 Supplier Landscape
  - 15.1 Abbott
    - 15.1.1 Company Overview
    - 15.1.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)



- 15.1.3 Demographic Reach and Achievements
- 15.1.4 Mergers and Acquisitions
- 15.1.5 Certifications
- 15.2 AbbVie Inc.
  - 15.2.1 Company Overview
  - 15.2.2 Product Portfolio
  - 15.2.3 Demographic Reach and Achievements
  - 15.2.4 Mergers and Acquisitions
  - 15.2.5 Certifications
- 15.3 Bayer AG
  - 15.3.1 Company Overview
  - 15.3.2 Product Portfolio
  - 15.3.3 Demographic Reach and Achievements
  - 15.3.4 Mergers and Acquisitions
  - 15.3.5 Certifications
- 15.4 Pfizer Inc.
  - 15.4.1 Company Overview
  - 15.4.2 Product Portfolio
  - 15.4.3 Demographic Reach and Achievements
  - 15.4.4 Mergers and Acquisitions
  - 15.4.5 Certifications
- 15.5 Ipsen Pharma
  - 15.5.1 Company Overview
  - 15.5.2 Product Portfolio
  - 15.5.3 Demographic Reach and Achievements
  - 15.5.4 Mergers and Acquisitions
  - 15.5.5 Certifications
- 15.6 Evotec SE
  - 15.6.1 Company Overview
  - 15.6.2 Product Portfolio
  - 15.6.3 Demographic Reach and Achievements
  - 15.6.4 Mergers and Acquisitions
  - 15.6.5 Certifications
- 15.7 Myovant Sciences GmbH
  - 15.7.1 Company Overview
  - 15.7.2 Product Portfolio
  - 15.7.3 Demographic Reach and Achievements
  - 15.7.4 Mergers and Acquisitions
  - 15.7.5 Certifications
- 15.8 Philogen S.p.A.
  - 15.8.1 Company Overview
  - 15.8.2 Product Portfolio
  - 15.8.3 Demographic Reach and Achievements
  - 15.8.4 Mergers and Acquisitions
  - 15.8.5 Certifications
- 15.9 Astellas Pharma Inc.
  - 15.9.1 Company Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisitions
- 15.9.5 Certifications
- 15.10 Orphagen Pharmaceuticals
  - 15.10.1 Company Overview
  - 15.10.2 Product Portfolio
  - 15.10.3 Demographic Reach and Achievements
  - 15.10.4 Mergers and Acquisitions
  - 15.10.5 Certifications
- 16 Global Endometriosis Treatment Market- Drugs Distribution Model (Additional Insight)
  - 16.1 Overview
  - 16.2 Potential Distributors
  - 16.3 Key Parameters for Distribution Partner Assessment
- 17 Payment Methods (Additional Insight)
  - 17.1 Government Funded
  - 17.2 Private Insurance
  - 17.3 Out-of-Pocket

\*Additional insights provided are customizable as per client requirements.

## Global Endometriosis Treatment Market Report and Forecast 2024-2032

Market Report | 2024-07-19 | 200 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to [support@scotts-international.com](mailto:support@scotts-international.com)

### ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact [support@scotts-international.com](mailto:support@scotts-international.com) or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-03"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)